Exact Sciences Co. (NASDAQ:EXAS) EVP Sarah Condella Sells 2,000 Shares

Exact Sciences Co. (NASDAQ:EXASGet Free Report) EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now owns 71,787 shares in the company, valued at $5,025,090. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sarah Condella also recently made the following trade(s):

  • On Thursday, March 28th, Sarah Condella sold 2,000 shares of Exact Sciences stock. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00.
  • On Friday, March 1st, Sarah Condella sold 1,724 shares of Exact Sciences stock. The stock was sold at an average price of $59.32, for a total transaction of $102,267.68.
  • On Tuesday, February 27th, Sarah Condella sold 1,880 shares of Exact Sciences stock. The stock was sold at an average price of $56.89, for a total transaction of $106,953.20.
  • On Friday, February 23rd, Sarah Condella sold 1,021 shares of Exact Sciences stock. The stock was sold at an average price of $59.72, for a total transaction of $60,974.12.
  • On Wednesday, February 21st, Sarah Condella sold 1,079 shares of Exact Sciences stock. The stock was sold at an average price of $61.50, for a total transaction of $66,358.50.
  • On Thursday, February 15th, Sarah Condella sold 965 shares of Exact Sciences stock. The stock was sold at an average price of $61.43, for a total transaction of $59,279.95.

Exact Sciences Trading Down 1.2 %

Shares of NASDAQ:EXAS opened at $72.82 on Thursday. The company’s 50 day moving average price is $62.29 and its two-hundred day moving average price is $65.12. Exact Sciences Co. has a 12-month low of $56.05 and a 12-month high of $100.77. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32.

Exact Sciences (NASDAQ:EXASGet Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. During the same quarter in the prior year, the firm posted ($0.72) EPS. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. As a group, sell-side analysts predict that Exact Sciences Co. will post -0.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

EXAS has been the topic of a number of research reports. Citigroup reiterated a “buy” rating and issued a $100.00 price target on shares of Exact Sciences in a research note on Wednesday. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. Wolfe Research initiated coverage on shares of Exact Sciences in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $95.00 price target on the stock. TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday, February 26th. Finally, Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target on the stock in a research note on Tuesday, January 2nd. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $97.44.

Get Our Latest Report on EXAS

Institutional Trading of Exact Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Exact Sciences by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 17,559,751 shares of the medical research company’s stock worth $1,299,070,000 after acquiring an additional 115,058 shares during the period. Capital World Investors lifted its holdings in shares of Exact Sciences by 7.8% during the 4th quarter. Capital World Investors now owns 7,468,145 shares of the medical research company’s stock worth $552,493,000 after acquiring an additional 539,498 shares during the period. Artisan Partners Limited Partnership lifted its holdings in shares of Exact Sciences by 12.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company’s stock worth $330,711,000 after acquiring an additional 508,764 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Exact Sciences by 3.7% during the 1st quarter. Geode Capital Management LLC now owns 2,591,057 shares of the medical research company’s stock worth $175,458,000 after acquiring an additional 91,883 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Exact Sciences by 11.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,858,380 shares of the medical research company’s stock worth $137,483,000 after acquiring an additional 192,372 shares during the period. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

(Get Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Articles

Insider Buying and Selling by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.